Clinical Trials

Trial Name Description
PET ABC Dr. Phillip Blanchette
Impact of 18F-FDG PET-CT versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer.
MAC.19 Dr. Steven Latosinsky
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
NSABP B51 BR Dr. S. Latosinsky
Not open yet - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically
REaCT G2 BR Dr. R. Fernandes
A Multi Center Study to Compare Administration Schedules of G-CSF (filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Neutropenia in Early Stage Breast Cancer
DUCHESS Dr. Francisco Perera
Evaluation of the Ductal Carcinoma in Situ Score for Decisions on Radiotherapy in Patients with Low/Intermediate Risk DCIS
MAC.20 Dr. Phillip Blanchette
"not yet open" Randomized Phase III trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer.
TreatER+ight BR Dr. T. Vandenberg
Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy +/- Targeted Therapy
MRI B-mets BR Dr. F. Perera
Magnetic Imaging of Brain Metastases in Breast Cancer Patients, a Pilot Study of the Value of the balanced steady state free precession imaging (bSSFP) sequence in Detecting Additional Brain Metastases
NRG BR002 Dr. Brian Yaremko
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer.
REaCT-BTA Dr. Phillip Blanchette
A pragmatic randomized, multicentre trail comparing 4-weekly versus 12-weekly administration of bone-targeted agents in patients with bone metastases from either castration-resistant prostate cancer or breast cancer - The REaCT-BTA Study.
IMpassion BR Dr. T. Vandenberg
A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locall

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada